Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can zinc help fight sepsis? early study explores dosing

NCT ID NCT01162109

Knowledge-focused Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study looked at how the body handles zinc in people with severe sepsis, a life-threatening infection that causes organ failure. Researchers gave different doses of intravenous zinc to 40 ICU patients on breathing machines and compared them to 15 healthy volunteers. The goal was to find safe doses and understand how zinc affects inflammation and immune function, not to prove it works as a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2010

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Severe sepsis * Requiring mechanical ventilation * 18 years or older Exclusion Criteria: * \>36 hours since meeting severe sepsis criteria4 * Expected ICU length of stay \<72 hours * Pre-existing gastrointestinal disease\* * Post-cardiac arrest with significant anoxic brain injury * Creatinine clearance \<40mL/min\* * Taking zinc supplement during past month\* * Has received zinc supplementation while hospitalized * Pregnant or lactating\* * AIDS with CD4\<200\* * Previous bone marrow or solid organ transplant\* * Receiving TPN with added zinc

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe sepsis

Contacts and locations

Locations

  • University of Vermont College of Medicine

    Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.